VVOS earnings analysis
What we found in VVOS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
The supplied 10-Q extract does not include the financial statements or MD&A needed to assess current-quarter revenue, margins, EPS, balance-sheet movements, cash flow, or beat/miss versus the $5.726 million revenue and -$0.40 EPS estimates. The filing highlights settlement completion and financing activity, but also emphasizes that the SCN-based operating model remains unproven and that secured debt and financing covenants constrain liquidity. Overall sentiment is bearish because the disclosed risk profile is material and no quantitative operating improvement or guidance is provided in the supplied text.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Controls assessed as effective
- Management stated that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.
- Ortho-Tain litigation settled
- The Ortho-Tain litigation was resolved through a confidential settlement and release agreement entered into on March 13, 2026; the agreement also restricts use of “Guide” or “Guides” in formal product names.
- New financing securities disclosed
- The company disclosed issuance of a Series A Convertible Preferred Stock certificate of designation dated July 7, 2026, along with financing-related securities purchase and registration-rights agreements dated June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Unproven SCN business model
- The new sleep-center sales and distribution model, including the June 2025 SCN acquisition, is described as unproven and supported by limited operating history; the company stated its prior 2024 Rebis Health collaboration did not meet expectations.
- Debt and financing constraints
- The company issued an $8.25 million secured promissory note to finance the SCN acquisition. Although part of the debt was exchanged in August 2026, a portion remains outstanding and secured, while future debt or equity financings above $2.5 million in aggregate require Streeterville consent.
- Corporate-practice legal exposure
- The company warned that its arrangements with SCN physicians could implicate corporate-practice-of-medicine and fee-splitting laws, whose interpretation varies significantly by state; noncompliance could result in penalties, damages, fines, or lost revenue.
What they said about what is next.
The provided 10-Q extract contains no quantitative revenue or EPS outlook, and no explicit numeric guidance. Outlook deferred/not provided in the supplied filing text.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 20, 2026
- Vivos Therapeutics reported disappointing Q4 results, with actual revenue of $3,824,000 falling significantly short of consensus estimates of $7,258,002, reflecting a 47.31% miss. The company recorded a diluted EPS of…
- 10-K · April 15, 2026
- The company is executing a strategic pivot from a dentist-focused distribution model toward a medical-provider focused model (branded Sleep and Airway Medicine Centers) that includes acquisitions and alliances…
- 10-Q · August 14, 2024
- Vivos Therapeutics reported Q2 revenue of $4,054,000 (three months ended June 30, 2024), up from $3,419,000 in the prior quarter and $3,395,000 in Q2 2023, with gross margin expanding to 65.4% and an improved operating…
- 10-Q · May 14, 2024
- Vivos Therapeutics reported Q1 revenue of $3,419,000 and GAAP net loss of $3,763,000 (loss per share $1.63). Revenue declined versus the prior-year quarter (Q1 2023 revenue $3,857,000) while operating expenses fell to…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing VVOS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever